Followers | 250 |
Posts | 14020 |
Boards Moderated | 3 |
Alias Born | 07/07/2006 |
Sunday, October 18, 2009 5:30:37 AM
keep in mind this was a very mixed patient group,
with a lot of patients allready very far deteriorated
also the number of patient with 100 or so is not that big,
but it gives some rationale to wait and see what the tiny number of USA pals patients might or might not see.
those are just a handfull of patients and they are monitored/registered on paper and with video as well as part of their IND acces to iplex.
Iplex still has apoptotic properties with the igf1bp3 component of the drug, and still proven to induce muscular, bone and neurological growth.Also shown to have better safety profile then free igf1.
A potential to ease some suffering in ALS would greatly add value to current value of iplex though.
FDA Position on Allowing Patients with ALS Access to Iplex under an IND fpor those whom applied before march 6th. As well as a lottery based trial form in future IND applications to ensure some form of further data collection.
http://www.fda.gov/cder/drug/infopage/mecasermin_rinfabate/FDA_statement.htm
Based on this data:
Iplex in ALS patients - RESULTS from italian Expaned Acces Program
http://www.fda.gov/cder/drug/infopage/mecasermin_rinfabate/Iplex_experience.pdf
In the patients summarized above, the ALSFRS-R decline from pre-treatment through last available ALSFRS-R value is 0.38 points per month. In 25% of these patients, on-treatment ALSFRS-R values either did not change over time or slightly increased.
To date, 54 patients have been treated for at least 6 months and have both pre-treatment and 6-month ALSFRS-R values. In this cohort, pre-treatment ALSFRS-R is 30.0 ± 7.9, 6-month ALSFRS-R is 25.7 ± 9.6, and the ALSFRS-R decline from pre-treatment through the last available ALSFRS-R value is 0.68 points per month. In 20% of these patients, on-treatment ALSFRS-R values did not change over time or slightly increased.
at 12 months(!!)
In the patients summarized above, the ALSFRS-R decline from pre-treatment through last available ALSFRS-R value is 0.38 points per month. In 25% of these patients, on-treatment ALSFRS-R values either did not change over time or slightly increased.
Recent INSM News
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 05/03/2024 12:00:00 PM
- Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024 • PR Newswire (US) • 04/25/2024 12:00:00 PM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 04/05/2024 12:00:00 PM
- Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference • PR Newswire (US) • 03/27/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 01:27:59 PM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 03/05/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:08:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:05:35 PM
- Insmed To Present at Three March Conferences • PR Newswire (US) • 02/29/2024 01:00:00 PM
- Actress Jane Seymour and Insmed Raise Awareness of "Unseenism" and Empower People to Speak Up When It Comes to Their Health • PR Newswire (US) • 02/28/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 12:58:04 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/22/2024 12:43:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/22/2024 12:00:23 PM
- Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update • PR Newswire (US) • 02/22/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/16/2024 10:43:57 PM
- Insmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference Call on Thursday, February 22, 2024 • PR Newswire (US) • 02/08/2024 01:00:00 PM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 02/02/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 09:06:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 09:05:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 09:13:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 09:11:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 09:10:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 09:08:45 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM